[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LifeBiotic Medical Research Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100649007","lcs103-herbal-formula-for-secondary-prevention-of-non-muscle-invasive-urothelial-carcinoma-of-the-bladder-100649007",false,"NCT07728474","LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder","LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder - Phase IIA Randomized Controlled Trial","LCS103","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years.\n* Non-muscle invasive urothelial carcinoma, histologically confirmed by TURBT procedure within 3 months before enrollment.\n* Complete resection of bladder tumor in recent TURBT.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Inability to swallow tablets (esophageal stricture, feeding through gastrostomy).\n* Ineligibility for SOC therapy such as BCG instillations (where appropriate).\n* Upper tract urothelial carcinoma within the past 2 years.\n* Any malignancy other than NMIBC, active or systemically treated within the past 2 years (not including localized cutaneous basal cell or squamous cell carcinoma).\n* Estimated life expectancy \\\u003C 5 years.\n* Pregnant women, and women planning future pregnancy or wishing to preserve fertility.\n* Investigator evaluation of a physical or mental condition limiting a patient's ability to participate in the study.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a phase IIA, single-site, randomized, controlled, open-label clinical trial evaluating the safety and efficacy of the LCS103 oral herbal formula for the secondary prevention of NMIBC. The study will include 60 participants randomized 1:1 to either the investigational or control arm.\n\nPatients in the investigational arm will receive three oral tablets of LCS103 herbal formula twice daily for 1 year, in addition to the SOC recommended per risk group:\n\n* Low Risk: Cystoscopic follow-up at 3 \\& 9 months and yearly thereafter.\n* Intermediate Risk: 1-year intravesical instillations of BCG. Cystoscopic follow-up at 3 \\& 9 months, then biannually for 2 years and yearly thereafter.\n* High Risk: 3-year intravesical instillations of BCG. Cystoscopy and urine cytology every 3 months for 2 years, then biannually thereafter.\n\nParticipants in the control arm will receive SOC treatment as mentioned above. After 1 year, the investigational treatment will be stopped, and all participants will continue SOC treatment and surveillance.\n\nThe enrollment period is expected to be 1 year. The study will be terminated after the final visit of the last patient. The total study duration is expected to be 2 years.",[27],"Non-muscle Invasive Bladder Cancer (NMIBC)",[29,30,31],"NMIBC","Bladder Cancer","Non-Muscle Invasive Bladder Cancer","RECRUITING","2026-07-28",{"date":35,"type":36},"2026-07-29","ACTUAL",{"date":38,"type":21},"2026-07",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"LifeBiotic Medical Research Ltd.","INDUSTRY",""]